A detailed history of Cresset Asset Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cresset Asset Management, LLC holds 15,248 shares of CRSP stock, worth $809,973. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,248
Previous 13,637 11.81%
Holding current value
$809,973
Previous $853,000 21.81%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $97,739 - $143,572
1,611 Added 11.81%
15,248 $1.04 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $114,469 - $213,941
2,964 Added 27.77%
13,637 $853,000
Q3 2023

Nov 14, 2023

SELL
$45.39 - $59.0 $2,224 - $2,891
-49 Reduced 0.46%
10,673 $484,000
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $466,085 - $726,629
10,722 New
10,722 $601,000
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $162,328 - $277,231
-3,755 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $177,069 - $263,789
-3,329 Reduced 46.99%
3,755 $236,000
Q4 2021

Feb 10, 2022

SELL
$70.09 - $111.29 $890,283 - $1.41 Million
-12,702 Reduced 64.2%
7,084 $537,000
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $73,834 - $104,948
670 Added 3.5%
19,786 $2.21 Million
Q2 2021

Aug 10, 2021

BUY
$100.84 - $161.89 $152,570 - $244,939
1,513 Added 8.6%
19,116 $3.1 Million
Q1 2021

May 12, 2021

BUY
$110.72 - $210.04 $600,434 - $1.14 Million
5,423 Added 44.52%
17,603 $2.15 Million
Q4 2020

Feb 11, 2021

BUY
$79.67 - $173.23 $55,051 - $119,701
691 Added 6.01%
12,180 $1.87 Million
Q3 2020

Nov 13, 2020

BUY
$78.5 - $100.64 $372,325 - $477,335
4,743 Added 70.31%
11,489 $961,000
Q2 2020

Aug 04, 2020

BUY
$38.5 - $76.05 $259,721 - $513,033
6,746 New
6,746 $496,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.14B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Cresset Asset Management, LLC Portfolio

Follow Cresset Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cresset Asset Management, LLC with notifications on news.